CN115836052A - (1s)-1-苯基-2-吡啶-2-基乙胺的局部制剂 - Google Patents

(1s)-1-苯基-2-吡啶-2-基乙胺的局部制剂 Download PDF

Info

Publication number
CN115836052A
CN115836052A CN202180044182.0A CN202180044182A CN115836052A CN 115836052 A CN115836052 A CN 115836052A CN 202180044182 A CN202180044182 A CN 202180044182A CN 115836052 A CN115836052 A CN 115836052A
Authority
CN
China
Prior art keywords
acid
pharmaceutical formulation
weight
pharmaceutically acceptable
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044182.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·伯曼
R·库马尔
C·M·康威
M·K·多诺霍
A·K·雷卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Pharmaceutical Holding Co Ltd
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of CN115836052A publication Critical patent/CN115836052A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN202180044182.0A 2020-06-23 2021-06-23 (1s)-1-苯基-2-吡啶-2-基乙胺的局部制剂 Pending CN115836052A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043075P 2020-06-23 2020-06-23
US63/043,075 2020-06-23
PCT/US2021/038564 WO2021262779A1 (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Publications (1)

Publication Number Publication Date
CN115836052A true CN115836052A (zh) 2023-03-21

Family

ID=79281832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044182.0A Pending CN115836052A (zh) 2020-06-23 2021-06-23 (1s)-1-苯基-2-吡啶-2-基乙胺的局部制剂

Country Status (12)

Country Link
US (1) US12564579B2 (https=)
EP (1) EP4168116A4 (https=)
JP (1) JP2023531918A (https=)
KR (1) KR20230026449A (https=)
CN (1) CN115836052A (https=)
AU (1) AU2021297823A1 (https=)
BR (1) BR112022025900A2 (https=)
CA (1) CA3187140A1 (https=)
IL (1) IL299308A (https=)
MX (1) MX2022016183A (https=)
PH (1) PH12022553502A1 (https=)
WO (1) WO2021262779A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220093A2 (en) * 2023-04-20 2024-10-24 LifeActive, Inc. Transdermal delivery formulations and methods for the manufacture thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1068566A (zh) * 1991-07-17 1993-02-03 美国辉瑞有限公司 用作抗缺血剂的2-(4-羟基哌啶子基)-1-烷醇
CN1081669A (zh) * 1992-04-03 1994-02-09 美国菲索斯公司 用于治疗神经变性疾病的化合物
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
WO2018098344A1 (en) * 2016-11-28 2018-05-31 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
WO2020041329A1 (en) * 2018-08-20 2020-02-27 Yale University Combination therapy for treating or preventing depression or other mood diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58991B1 (sr) 2013-11-05 2019-08-30 Astrazeneca Ab Prolekovi nmda antagonista

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1068566A (zh) * 1991-07-17 1993-02-03 美国辉瑞有限公司 用作抗缺血剂的2-(4-羟基哌啶子基)-1-烷醇
CN1081669A (zh) * 1992-04-03 1994-02-09 美国菲索斯公司 用于治疗神经变性疾病的化合物
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
WO2018098344A1 (en) * 2016-11-28 2018-05-31 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
WO2020041329A1 (en) * 2018-08-20 2020-02-27 Yale University Combination therapy for treating or preventing depression or other mood diseases

Also Published As

Publication number Publication date
IL299308A (en) 2023-02-01
WO2021262779A1 (en) 2021-12-30
EP4168116A4 (en) 2024-07-10
AU2021297823A1 (en) 2023-02-16
KR20230026449A (ko) 2023-02-24
US20230190719A1 (en) 2023-06-22
EP4168116A1 (en) 2023-04-26
CA3187140A1 (en) 2021-12-30
US12564579B2 (en) 2026-03-03
JP2023531918A (ja) 2023-07-26
MX2022016183A (es) 2023-02-13
PH12022553502A1 (en) 2024-04-22
BR112022025900A2 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
US6455066B1 (en) Intradermal-penetration agents for topical local anesthetic administration
US7186260B2 (en) Medicated wrap
AU2001245449A1 (en) Intradermal-penetration agents for topical local anesthetic administration
US20070117828A1 (en) Pharmaceutical compositions
US20130209585A1 (en) Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
WO2008021847A2 (en) Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent
EP2640370A2 (en) Compositions for transdermal delivery of active agents
CA2407008C (en) Medicated wrap
US20070053968A1 (en) Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts
US12564579B2 (en) Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine
US20060276550A1 (en) Topical compositions of ketamine and butamben and methods of their use
US20070054964A1 (en) Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230321

WD01 Invention patent application deemed withdrawn after publication